Alzheimer's Drug Slows Memory Decline by 54% and Removes Harmful Brain Protein Tangles

An experimental Alzheimer's drug was associated with 54 per cent less decline on a memory and thinking test over almost two years, but its phase two trial missed its primary endpoint. Biogen announced the diranersen results on 17 November, following the presentation of data from the CELIA study at the Clinical Trials on Alzheimer's Disease conference in Boston.
The study involved 416 people with mild cognitive impairment or mild dementia due to Alzheimer's. Diranersen is not approved by any regulator. The 54 per cent figure was reported by The Telegraph, while other reported measures showed smaller effects.
Alzheimer's is associated with a build-up of proteins, including amyloid and tau. The first drugs licensed in the UK to slow the disease target amyloid. Diranersen, by contrast, aims to reduce tau production. However, it remains experimental, and there is no cure that stops or reverses Alzheimer's.
What the Diranersen Alzheimer's Trial Found
Researchers reported that brain scans showed levels of aggregated tau falling below participants' starting levels. Professor Jeffrey Cummings, a study co-author, told the conference: 'We reversed Alzheimer pathology. We removed tau tangles.'
Professor Reisa Sperling, a Harvard Medical School neurologist and co-author, called the scan findings 'thrilling.'
Those statements reflect the researchers' interpretation of the scan results. They do not establish that patients' lost abilities were restored. The reported 54 per cent difference refers to slower decline on a test, not recovery.
The 54 per cent figure was reported for a low dose over nearly two years. Reports of Biogen's data put the slowing at 30 to 46 per cent across other measures of daily living, cognition and disease progression for the 60mg dose, administered twice a year, which showed the largest effects.
Why the Diranersen Results Need Context
At 96 weeks, researchers compared participants who had received diranersen from the start with those initially assigned to placebo. The placebo-controlled period lasted 18 months. During the extension phase, participants originally assigned to placebo had received either no active treatment or one dose.
Biogen said in May that the study had failed to meet its primary endpoint, which assessed dose response.
Diranersen was discovered by Ionis Pharmaceuticals and licensed to Biogen in 2019. The gene-silencing treatment blocks RNA messages that instruct brain cells to produce tau. It is administered by lumbar puncture into the fluid surrounding the spinal cord.
Biogen's head of development, Priya Singhal, said the results showed 'sustained clinical benefit' and an 'increasing magnitude of effect.' Biogen funded the trial.
Side Effects and What Comes Next
Reported side effects included pain linked to lumbar punctures, headaches and confusion. Headaches and confusion were more common at higher doses. Biogen said the treatment was generally well tolerated and reported no new safety concerns over two years.
Richard Oakley, associate director for research and innovation at Alzheimer's Society, called the results 'very encouraging.' He said the approach was interesting because it targets tau at its source, but stressed that confirmation in a phase three trial is essential.
A larger phase three trial is planned to test whether diranersen reliably slows decline and to assess its long-term safety. UK recruitment is expected to begin in the spring, the Telegraph reported. The current findings concern people with early Alzheimer's and do not show whether the drug would work for everyone with the disease.